Lantern Pharma (NASDAQ: LTRN) announced it will host its first live, public demonstration of its withZeta.ai multi-agentic AI co-scientist platform on April 30, 2026, with two sessions scheduled to accommodate global audiences. The event will feature a real-time, interactive demonstration led by CEO Panna Sharma, showcasing the platform’s ability to execute complex oncology research workflows by integrating clinical, molecular and scientific datasets. Lantern said the platform is designed to accelerate drug discovery timelines, particularly in rare cancers, while supporting a scalable, subscription-based commercial model.
The demonstration marks a significant milestone for Lantern Pharma as it transitions withZeta.ai from an internal research tool to a commercially available platform. The company has emphasized that the platform’s multi-agentic architecture enables it to perform tasks that traditionally require extensive manual analysis, such as identifying novel drug targets, predicting drug responses, and optimizing clinical trial designs. By integrating diverse data sources—including genomic, transcriptomic, and clinical trial data—withZeta.ai aims to reduce the time and cost associated with bringing new cancer therapies to market.
Lantern Pharma’s CEO Panna Sharma stated that the live demo will provide an unprecedented look at how AI can transform cancer research. The company believes that withZeta.ai’s subscription model could generate a new revenue stream while also advancing its own pipeline of precision oncology drugs, including LP-184, LP-284, and LP-300. LP-184 is being developed for solid tumors and pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. LP-284 targets hematologic and solid tumors via TC-NER inhibition, and LP-300 is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma.
The announcement comes as Lantern Pharma continues to build out its AI capabilities, with an AI Center of Excellence in Bengaluru, India, and headquarters in Dallas, Texas. The company’s proprietary RADR platform, which underpins withZeta.ai, has been used to analyze over 300 billion data points and support collaborations with academic institutions and pharmaceutical partners. For more details, the full press release is available at https://ibn.fm/wzevl.
The live public demonstration underscores the growing trend of AI-driven drug discovery and the potential for platforms like withZeta.ai to reshape the pharmaceutical landscape. By opening its technology to the broader biomedical community through a subscription model, Lantern aims to democratize access to advanced AI tools while generating recurring revenue. The event will likely attract attention from investors, researchers, and pharmaceutical companies interested in leveraging AI to expedite oncology research.
As the company prepares for the demonstration, it continues to advance its clinical pipeline. Lantern Pharma’s focus on rare and difficult-to-treat cancers, combined with its AI-driven approach, positions it at the forefront of precision oncology. The success of withZeta.ai could not only accelerate Lantern’s own drug development efforts but also establish the platform as a valuable resource for the entire drug development ecosystem.
